JP2019519499A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519499A5 JP2019519499A5 JP2018559738A JP2018559738A JP2019519499A5 JP 2019519499 A5 JP2019519499 A5 JP 2019519499A5 JP 2018559738 A JP2018559738 A JP 2018559738A JP 2018559738 A JP2018559738 A JP 2018559738A JP 2019519499 A5 JP2019519499 A5 JP 2019519499A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662335743P | 2016-05-13 | 2016-05-13 | |
| US62/335,743 | 2016-05-13 | ||
| US201662340142P | 2016-05-23 | 2016-05-23 | |
| US62/340,142 | 2016-05-23 | ||
| US201662348546P | 2016-06-10 | 2016-06-10 | |
| US62/348,546 | 2016-06-10 | ||
| US201662350305P | 2016-06-15 | 2016-06-15 | |
| US62/350,305 | 2016-06-15 | ||
| US201662364920P | 2016-07-21 | 2016-07-21 | |
| US62/364,920 | 2016-07-21 | ||
| US201662374020P | 2016-08-12 | 2016-08-12 | |
| US62/374,020 | 2016-08-12 | ||
| US201762451274P | 2017-01-27 | 2017-01-27 | |
| US62/451,274 | 2017-01-27 | ||
| PCT/US2017/032397 WO2017197259A1 (en) | 2016-05-13 | 2017-05-12 | Combination of anti-pd-1 antibodies and radiation to treat cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519499A JP2019519499A (ja) | 2019-07-11 |
| JP2019519499A5 true JP2019519499A5 (https=) | 2020-06-18 |
| JP6999577B2 JP6999577B2 (ja) | 2022-01-18 |
Family
ID=58800911
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559739A Active JP7054680B2 (ja) | 2016-05-13 | 2017-05-12 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
| JP2018559738A Active JP6999577B2 (ja) | 2016-05-13 | 2017-05-12 | がんを処置するための抗ｐｄ－１抗体と放射線の組合せ |
| JP2022004089A Active JP7313493B2 (ja) | 2016-05-13 | 2022-01-14 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
| JP2023112057A Active JP7624033B2 (ja) | 2016-05-13 | 2023-07-07 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559739A Active JP7054680B2 (ja) | 2016-05-13 | 2017-05-12 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022004089A Active JP7313493B2 (ja) | 2016-05-13 | 2022-01-14 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
| JP2023112057A Active JP7624033B2 (ja) | 2016-05-13 | 2023-07-07 | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US20170327567A1 (https=) |
| EP (4) | EP3455258B1 (https=) |
| JP (4) | JP7054680B2 (https=) |
| KR (5) | KR20230152804A (https=) |
| CN (4) | CN116098997A (https=) |
| AU (3) | AU2017264955B2 (https=) |
| BR (1) | BR112018073291A2 (https=) |
| CA (2) | CA3023984A1 (https=) |
| CL (1) | CL2018003207A1 (https=) |
| CY (1) | CY1124901T1 (https=) |
| DK (3) | DK3455258T3 (https=) |
| ES (3) | ES2899954T3 (https=) |
| FI (2) | FI3932951T3 (https=) |
| HR (3) | HRP20220014T1 (https=) |
| HU (3) | HUE061874T2 (https=) |
| IL (4) | IL262562B2 (https=) |
| LT (2) | LT3455258T (https=) |
| MD (3) | MD3455259T2 (https=) |
| MX (4) | MX389733B (https=) |
| MY (2) | MY194085A (https=) |
| NZ (2) | NZ788452A (https=) |
| PH (1) | PH12018502263A1 (https=) |
| PL (3) | PL3932951T3 (https=) |
| PT (3) | PT3455258T (https=) |
| RS (3) | RS64218B1 (https=) |
| SG (2) | SG11201809554VA (https=) |
| SI (3) | SI3455259T1 (https=) |
| SM (2) | SMT202300070T1 (https=) |
| TW (4) | TWI755395B (https=) |
| UA (1) | UA124151C2 (https=) |
| WO (2) | WO2017197259A1 (https=) |
| ZA (2) | ZA201807051B (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| US20210363242A1 (en) * | 2018-01-16 | 2021-11-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
| MA52789A (fr) | 2018-02-13 | 2021-04-14 | Merck Sharp & Dohme | Méthodes de traitement du cancer avec des anticorps anti-pd-1 |
| EP3775258A4 (en) | 2018-03-28 | 2022-01-26 | Board of Regents, The University of Texas System | IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES |
| CN111821434A (zh) * | 2019-04-17 | 2020-10-27 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 |
| MX2020011588A (es) * | 2018-05-03 | 2020-12-07 | Shanghai Epimab Biotherapeutics Co Ltd | Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas. |
| TW202504917A (zh) * | 2018-06-21 | 2025-02-01 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法 |
| JP7466519B2 (ja) | 2018-07-23 | 2024-04-12 | ガーダント ヘルス， インコーポレイテッド | 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム |
| JP7539367B2 (ja) | 2018-08-31 | 2024-08-23 | ガーダント ヘルス， インコーポレイテッド | 無細胞ｄｎａにおけるマイクロサテライト不安定性の検出 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| JP2022508935A (ja) * | 2018-10-19 | 2022-01-19 | センワ バイオサイエンシズ，インコーポレイティッド | がん治療における免疫モジュレーションのための組合せ |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| HUE067601T2 (hu) | 2018-11-14 | 2024-10-28 | Regeneron Pharma | PD-1 inhibitorok intraléziós beadása a bõrrák kezelésére |
| EP3880231A1 (en) * | 2018-11-16 | 2021-09-22 | NeoImmuneTech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
| EA202191556A1 (ru) * | 2018-12-03 | 2021-10-14 | Фьюжн Фармасьютикалз Инк. | Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек |
| WO2020118216A1 (en) * | 2018-12-08 | 2020-06-11 | Board Of Regents, The University Of Texas System | Identification and targeting of tumor promoting carcinoma associated fibroblasts for diagnosis and treatment of cancer and other diseases |
| WO2020123388A1 (en) | 2018-12-11 | 2020-06-18 | Board Of Regents, The University Of Texas System | Radiotherapies and uses thereof |
| MX2021008604A (es) * | 2019-01-21 | 2021-10-26 | Sanofi Sa | Arn terapeutico para tumores solidos cancerigenos en etapa avanzada. |
| WO2020156500A1 (zh) * | 2019-01-31 | 2020-08-06 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体治疗头颈癌的用途 |
| MA55084A (fr) * | 2019-02-28 | 2022-01-05 | Regeneron Pharma | Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau |
| WO2020222231A1 (en) | 2019-04-28 | 2020-11-05 | Institut Pasteur De Montevideo. | Ionic channel modulation as a method for treating tumors through inflammasome activation |
| SG11202111262XA (en) * | 2019-05-13 | 2021-11-29 | Regeneron Pharma | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
| EP4021568A4 (en) * | 2019-08-27 | 2023-11-01 | Montefiore Medical Center | Post-ablative modulation of radiation therapy |
| US20210169979A1 (en) * | 2019-12-05 | 2021-06-10 | The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges | System and method for sonosensitized cancer immunotherapy with nanoparticles |
| KR102195221B1 (ko) | 2019-12-31 | 2020-12-24 | 서울대학교산학협력단 | 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물 |
| JP2023512214A (ja) | 2020-01-28 | 2023-03-24 | リフレクション メディカル， インコーポレイテッド | 放射性核種および外部ビーム放射線療法の共同最適化 |
| CN113318226A (zh) * | 2020-02-28 | 2021-08-31 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体联合放射性射线治疗肺癌的方法 |
| CN111840585B (zh) * | 2020-07-20 | 2022-05-03 | 厦门大学 | 一种用于肿瘤免疫治疗的药物组合 |
| JP2023540217A (ja) * | 2020-08-26 | 2023-09-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｐｄ－１阻害剤を投与することによりがんを処置する方法 |
| JP2023542490A (ja) * | 2020-09-03 | 2023-10-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｐｄ－１阻害剤を投与することによりがん疼痛を処置する方法 |
| KR20230141869A (ko) * | 2021-02-11 | 2023-10-10 | 리제너론 파마슈티칼스 인코포레이티드 | 신보조 요법으로서 pd-1 저해제의 투여에 의한 암 치료 방법 |
| EP4313123A1 (en) * | 2021-03-23 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor |
| CN115125211A (zh) * | 2021-03-24 | 2022-09-30 | 核工业总医院 | 免疫治疗疗效评价用结肠癌腹膜转移小鼠模型 |
| CN113368226B (zh) * | 2021-06-30 | 2021-11-30 | 上海力沃生物科技有限公司 | 含有dc瘤苗的药物组合物及其在治疗癌症中的应用 |
| EP4382135A4 (en) * | 2021-08-06 | 2025-10-08 | Rznomics Inc | CANCER-SPECIFIC TRANS-SPLICING RIBOZYME AS A GENE THERAPY PRODUCT COMBINED WITH RADIOTHERAPY |
| EP4476263A4 (en) * | 2022-02-09 | 2026-01-28 | Dragonfly Therapeutics Inc | PHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO EGFR, NKG2D AND CD16 |
| EP4662238A1 (en) * | 2023-02-06 | 2025-12-17 | F. Hoffmann-La Roche AG | Combination therapy and uses thereof |
| WO2025040080A1 (en) * | 2023-08-21 | 2025-02-27 | Beigene Switzerland Gmbh | Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy |
| WO2025117889A2 (en) * | 2023-11-30 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer by administering a combination therapy including a neoadjuvant pd-1 inhibitor |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| EP1210424B1 (en) | 1999-08-23 | 2007-02-07 | Dana-Farber Cancer Institute, Inc. | Novel b7-4 molecules and uses therefor |
| AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| JP2004501631A (ja) | 2000-06-28 | 2004-01-22 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| AU2002258941A1 (en) | 2001-04-20 | 2002-11-05 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| JP2004104681A (ja) | 2002-09-12 | 2004-04-02 | Renesas Technology Corp | 入力バッファ回路 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| JP4663394B2 (ja) | 2005-05-11 | 2011-04-06 | ダイセルポリマー株式会社 | 難めっき性被覆剤及びめっきの前処理方法 |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| EP1997887B1 (en) | 2006-03-03 | 2013-09-04 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of cell surface functional molecule |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US9243052B2 (en) | 2007-08-17 | 2016-01-26 | Daniel Olive | Method for treating and diagnosing hematologic malignancies |
| EP2195342A1 (en) | 2007-09-07 | 2010-06-16 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| JP5794917B2 (ja) | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ | Ｐｄ−１特異抗体およびその使用 |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| EP3375791A1 (en) | 2009-09-30 | 2018-09-19 | Memorial Sloan Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| CN103261217B (zh) | 2010-11-11 | 2017-04-26 | 港大科桥有限公司 | 可溶性 pd‑1变体、融合构建体及其用途 |
| ES2676205T3 (es) * | 2011-03-31 | 2018-07-17 | Merck Sharp & Dohme Corp. | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| GB201120527D0 (en) | 2011-11-29 | 2012-01-11 | Ucl Business Plc | Method |
| US20140370012A1 (en) | 2012-01-27 | 2014-12-18 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| AU2013256010B2 (en) | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
| WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| US20130303250A1 (en) | 2012-05-11 | 2013-11-14 | Ryan Moore | Method of Playing a Card Game |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| WO2013181452A1 (en) | 2012-05-31 | 2013-12-05 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| EP3626309B1 (en) * | 2012-08-13 | 2023-03-08 | The Rockefeller University | Lxrbeta agonist for the treatment of cancer |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| PL2904011T3 (pl) | 2012-10-02 | 2018-01-31 | Bristol Myers Squibb Co | Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka |
| CA2889182A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| RU2718988C2 (ru) | 2013-02-22 | 2020-04-15 | Куревак Аг | Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение |
| ES2812208T3 (es) | 2013-03-14 | 2021-03-16 | Bristol Myers Squibb Co | Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso |
| KR102389677B1 (ko) | 2013-03-15 | 2022-04-21 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CA2916681A1 (en) | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| CA2917858A1 (en) | 2013-08-02 | 2015-02-05 | Aduro Biotech Holdings, Europe B.V. | Combining cd27 agonists and immune checkpoint inhibition for immune stimulation |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| CA2920113A1 (en) | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
| SG11201601763SA (en) | 2013-09-20 | 2016-04-28 | Bristol Myers Squibb Co | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| MX375378B (es) | 2013-09-27 | 2025-03-06 | Genentech Inc | Formulaciones de anticuerpos anti-pdl1. |
| EP3079772B1 (en) | 2013-12-10 | 2020-02-05 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue |
| UA129760C2 (uk) | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| AU2014364606A1 (en) * | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| JP2017515859A (ja) | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| SG10201912986PA (en) | 2014-05-28 | 2020-02-27 | Agenus Inc | Anti-gitr antibodies and methods of use thereof |
| PT3151921T (pt) | 2014-06-06 | 2019-11-21 | Bristol Myers Squibb Co | Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| ES2783424T3 (es) | 2014-06-19 | 2020-09-17 | Regeneron Pharma | Animales no humanos que tienen un gen de muerte celular programada 1 humanizado |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| WO2016070051A2 (en) * | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| ES2791950T3 (es) | 2015-02-03 | 2020-11-06 | Ventana Med Syst Inc | Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1) |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| WO2016191751A1 (en) | 2015-05-28 | 2016-12-01 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| MX394957B (es) | 2015-09-03 | 2025-03-24 | Ono Pharmaceutical Co | Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1". |
| JP7126941B2 (ja) | 2015-12-22 | 2022-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ |
| KR20190003938A (ko) | 2016-02-25 | 2019-01-10 | 셀 메디카 스위처란트 아게 | 면역치료를 위한 변형된 세포 |
| EP3548515B1 (en) | 2016-12-01 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
-
2017
- 2017-05-11 TW TW106115562A patent/TWI755395B/zh active
- 2017-05-11 TW TW112143833A patent/TWI910495B/zh active
- 2017-05-11 TW TW106115563A patent/TWI786044B/zh active
- 2017-05-11 TW TW111148425A patent/TWI822521B/zh active
- 2017-05-12 FI FIEP21191931.1T patent/FI3932951T3/fi active
- 2017-05-12 ES ES17726759T patent/ES2899954T3/es active Active
- 2017-05-12 PT PT177267598T patent/PT3455258T/pt unknown
- 2017-05-12 KR KR1020237036612A patent/KR20230152804A/ko not_active Ceased
- 2017-05-12 SI SI201731342T patent/SI3455259T1/sl unknown
- 2017-05-12 IL IL262562A patent/IL262562B2/en unknown
- 2017-05-12 NZ NZ788452A patent/NZ788452A/en unknown
- 2017-05-12 MD MDE20190335T patent/MD3455259T2/ro unknown
- 2017-05-12 MY MYPI2018703920A patent/MY194085A/en unknown
- 2017-05-12 FI FIEP17727767.0T patent/FI3455259T3/fi active
- 2017-05-12 CA CA3023984A patent/CA3023984A1/en active Pending
- 2017-05-12 CN CN202310111307.8A patent/CN116098997A/zh active Pending
- 2017-05-12 LT LTEPPCT/US2017/032408T patent/LT3455258T/lt unknown
- 2017-05-12 US US15/593,897 patent/US20170327567A1/en active Pending
- 2017-05-12 SG SG11201809554VA patent/SG11201809554VA/en unknown
- 2017-05-12 RS RS20230397A patent/RS64218B1/sr unknown
- 2017-05-12 BR BR112018073291-5A patent/BR112018073291A2/pt not_active Application Discontinuation
- 2017-05-12 PL PL21191931.1T patent/PL3932951T3/pl unknown
- 2017-05-12 MX MX2018013847A patent/MX389733B/es unknown
- 2017-05-12 HR HRP20220014TT patent/HRP20220014T1/hr unknown
- 2017-05-12 DK DK17726759.8T patent/DK3455258T3/da active
- 2017-05-12 MD MDE20220619T patent/MD3932951T2/ro unknown
- 2017-05-12 HU HUE17727767A patent/HUE061874T2/hu unknown
- 2017-05-12 CN CN201780028425.5A patent/CN109153723B/zh active Active
- 2017-05-12 KR KR1020187036323A patent/KR102470294B1/ko active Active
- 2017-05-12 MD MDE20190333T patent/MD3455258T2/ro unknown
- 2017-05-12 SI SI201730995T patent/SI3455258T1/sl unknown
- 2017-05-12 HR HRP20230517TT patent/HRP20230517T1/hr unknown
- 2017-05-12 PL PL17727767.0T patent/PL3455259T3/pl unknown
- 2017-05-12 DK DK17727767.0T patent/DK3455259T5/da active
- 2017-05-12 AU AU2017264955A patent/AU2017264955B2/en active Active
- 2017-05-12 SG SG10202011110PA patent/SG10202011110PA/en unknown
- 2017-05-12 ES ES21191931T patent/ES2938321T3/es active Active
- 2017-05-12 EP EP17726759.8A patent/EP3455258B1/en active Active
- 2017-05-12 US US15/593,915 patent/US10457725B2/en active Active
- 2017-05-12 KR KR1020187036322A patent/KR102349056B1/ko active Active
- 2017-05-12 DK DK21191931.1T patent/DK3932951T5/da active
- 2017-05-12 RS RS20230164A patent/RS64014B1/sr unknown
- 2017-05-12 EP EP17727767.0A patent/EP3455259B1/en active Active
- 2017-05-12 HU HUE17726759A patent/HUE057781T2/hu unknown
- 2017-05-12 KR KR1020227038606A patent/KR102595561B1/ko active Active
- 2017-05-12 EP EP22203044.7A patent/EP4180459A1/en active Pending
- 2017-05-12 WO PCT/US2017/032397 patent/WO2017197259A1/en not_active Ceased
- 2017-05-12 NZ NZ788455A patent/NZ788455A/en unknown
- 2017-05-12 SI SI201731309T patent/SI3932951T1/sl unknown
- 2017-05-12 EP EP21191931.1A patent/EP3932951B1/en active Active
- 2017-05-12 HU HUE21191931A patent/HUE061417T2/hu unknown
- 2017-05-12 WO PCT/US2017/032408 patent/WO2017197263A1/en not_active Ceased
- 2017-05-12 IL IL318482A patent/IL318482A/en unknown
- 2017-05-12 PL PL17726759T patent/PL3455258T3/pl unknown
- 2017-05-12 IL IL302924A patent/IL302924B2/en unknown
- 2017-05-12 JP JP2018559739A patent/JP7054680B2/ja active Active
- 2017-05-12 SM SM20230070T patent/SMT202300070T1/it unknown
- 2017-05-12 LT LTEP21191931.1T patent/LT3932951T/lt unknown
- 2017-05-12 CN CN202310111383.9A patent/CN116407627A/zh active Pending
- 2017-05-12 PT PT211919311T patent/PT3932951T/pt unknown
- 2017-05-12 SM SM20220015T patent/SMT202200015T1/it unknown
- 2017-05-12 CA CA3023985A patent/CA3023985A1/en active Pending
- 2017-05-12 HR HRP20230236TT patent/HRP20230236T1/hr unknown
- 2017-05-12 JP JP2018559738A patent/JP6999577B2/ja active Active
- 2017-05-12 CN CN201780028431.0A patent/CN109153724B/zh active Active
- 2017-05-12 MY MYPI2022006224A patent/MY208872A/en unknown
- 2017-05-12 MX MX2018013848A patent/MX2018013848A/es unknown
- 2017-05-12 PT PT177277670T patent/PT3455259T/pt unknown
- 2017-05-12 AU AU2017264959A patent/AU2017264959B2/en active Active
- 2017-05-12 ES ES17727767T patent/ES2943640T3/es active Active
- 2017-05-12 RS RS20211610A patent/RS62783B1/sr unknown
- 2017-05-12 UA UAA201812344A patent/UA124151C2/uk unknown
- 2017-05-12 KR KR1020217040328A patent/KR102464774B1/ko active Active
-
2018
- 2018-10-23 ZA ZA2018/07051A patent/ZA201807051B/en unknown
- 2018-10-23 ZA ZA2018/07050A patent/ZA201807050B/en unknown
- 2018-10-24 PH PH12018502263A patent/PH12018502263A1/en unknown
- 2018-10-24 IL IL262561A patent/IL262561B/en unknown
- 2018-11-12 MX MX2022001120A patent/MX2022001120A/es unknown
- 2018-11-12 MX MX2022001123A patent/MX2022001123A/es unknown
- 2018-11-12 CL CL2018003207A patent/CL2018003207A1/es unknown
-
2019
- 2019-09-03 US US16/559,159 patent/US11505600B2/en active Active
-
2022
- 2022-01-10 CY CY20221100022T patent/CY1124901T1/el unknown
- 2022-01-14 JP JP2022004089A patent/JP7313493B2/ja active Active
- 2022-10-14 US US18/046,576 patent/US20230227542A1/en active Pending
-
2023
- 2023-07-07 JP JP2023112057A patent/JP7624033B2/ja active Active
-
2024
- 2024-09-24 AU AU2024220021A patent/AU2024220021A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519499A5 (https=) | ||
| FI3455259T3 (fi) | Anti-PD-1-vasta-aineiden ja sädehoidon yhdistelmä syövän hoitoon | |
| JP2019515008A5 (https=) | ||
| JP2022050618A5 (https=) | ||
| JP7126941B2 (ja) | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ | |
| JP2020099324A5 (https=) | ||
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| JP2021528423A5 (https=) | ||
| JP2020508317A5 (https=) | ||
| JP2017533912A5 (https=) | ||
| JP2018518454A5 (https=) | ||
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| FI3313441T3 (fi) | Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla | |
| IL321717A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| IL278574B2 (en) | Glycan-interacting compounds and methods of use | |
| JP2018534933A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| JP2016528195A5 (https=) | ||
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2013520442A5 (https=) | ||
| JP2022500410A5 (https=) | ||
| JP2018512402A5 (https=) | ||
| JPWO2022270524A5 (https=) | ||
| JPWO2019246356A5 (https=) |